Regenxbio RGNX Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept rgnx:AccruedExpensesAndOtherCurrentLiabilities.
The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regenxbio's accrued expenses and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regenxbio's accrued expenses and other current liabilities?
- Regenxbio (RGNX) reported accrued expenses and other current liabilities of $21.89M in Q1 2026.
- How has Regenxbio's accrued expenses and other current liabilities changed year-over-year?
- Regenxbio's accrued expenses and other current liabilities decreased by 7.2% year-over-year, from $23.6M to $21.89M.
- What is the long-term trend for Regenxbio's accrued expenses and other current liabilities?
- Over 5 years (2020 to 2025), Regenxbio's accrued expenses and other current liabilities has grown at a -4.8% compound annual growth rate (CAGR), from $49.08M to $38.39M.
- What does accrued expenses and other current liabilities mean?
- This represents the aggregate of short-term obligations incurred by the company for goods or services received but not yet invoiced or paid by the balance sheet date. It serves as a measure of operational short-term debt and reflects the timing differences between expense recognition and cash outflow. Monitoring this balance helps investors assess the company's near-term working capital requirements and potential cash flow pressures.